Should we also be talking about allogeneic CAR-Ts? They are still a viable competitor, especially Allogene which has a 1L high-risk trial ongoing that can solve many of the issues highlighted here.
Allogeneic approaches definitely still have some outs, especially if they can figure out the durability issues and infections associated with the heavier LD required. Allogene is pursuing 1L LBCL though, not MM as its lead. In general though, the allogeneic field has culled or pivoted significantly allowing what were once more futuristic approaches, like in vivo, to close the gap.
Should we also be talking about allogeneic CAR-Ts? They are still a viable competitor, especially Allogene which has a 1L high-risk trial ongoing that can solve many of the issues highlighted here.
Allogeneic approaches definitely still have some outs, especially if they can figure out the durability issues and infections associated with the heavier LD required. Allogene is pursuing 1L LBCL though, not MM as its lead. In general though, the allogeneic field has culled or pivoted significantly allowing what were once more futuristic approaches, like in vivo, to close the gap.